First immunotherapeutic for lymphomas clears FDA

Non-Hodgkin's lymphomas (NHL) are a diverse group of malignancies that attack the B and T lymphocytes of the immune system. More than 50,000 Americans develop NHL annually, and nearly 50% of them die of the disease. Conventional treatment of NHL is limited to chemotherapy, with burdensome side effects and variable clinical outcomes. If the lymphoma is localized, the choice of therapy is radiation, but targeting external beam radiation to cancerous immune system cells throughout the body is difficult and complex.


For full article Click Here